Pharvaris
PHVS
31.28
-0.38
-1.20%
Pharvaris
US · PHVS
#2729 by market cap
Listed 2021
31.28
-0.38
-1.20%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
About Pharvaris
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
- Founded
- 2015
- CEO
- Mr. Berndt Modig
- Employees
- 129
- Headquarters
- Leiden, Zuid-Holland, Netherlands (the)
- Fiscal year end
- 12-31
- Website
- pharvaris.com
Company profile
- Exchange
- US
- Symbol
- PHVS
- Market-cap rank
- #2729
- Listing date
- 2021-02-05
- Market cap
- 2.21B
- Float cap
- 1.72B
- Shares out
- 70.79M
- Float shares
- 55.10M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 20:01:10 · For reference only, not investment advice and not tailored to your situation.
Pharvaris discussion 0 comments